跳转到主要内容


Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
快速连接

白皮书

Tech Sheet - Cabozantinib (S)-malate API

Tech Sheet - Cabozantinib (S)-malate API

Cabozantinib S-malate is an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity.

Dr. Reddy's API Offering*

  • We offer Cabozantinib S-malate – Crystalline form N2 (Innovator form).
  • Cabozantinib HCl is an alternate salt providing 505(b)(2) opportunities in the US and early launch opportunities in Europe, Brazil, Turkey, Mexico, and South Korea.
  • Dr. Reddy’s proposed synthetic process is IP-compliant.
  • We employ a quality-by-design (QbD) approach for efficient processes and high-quality output.
  • Effective control strategy for avoiding potential genotoxic and carcinogenic impurities
  • Assured process safety and scalability.
  • A short lead time of 120-180 days from the purchase order date (PO).

To learn more about our API offerings, please read the Tech sheet on Cabozantinib API by filling out the contact form below.

Note: *Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act and not for commercial sale.

Explore other Whitepapers:

Know More

Download Now

请填写下面的联系表以查看白皮书

给我们发电子邮件: api@drreddys.com | +91 40 49002222

免责声明

本目錄中的任何信息(包括對任何產品或服務的任何引用)均不構成銷售要約,或被解釋為代表銷售要約。受有效專利保護的產品不提供或供應用於商業用途。但是,只要存在此類監管豁免,就可以出於監管提交的目的提供此類產品的研究數量。買方應對各自市場的專利方案進行獨立評估,並承擔所有與專利相關的責任。在印度受有效專利保護的產品不可用於商業用途,但可用於第 107A 節。

X

Have you booked your
CPHI Japan meeting slot yet?

Join us at booth: 5N-12

17th-19th April 2024

East Halls 4, 5 & 6, Tokyo Big Sight, Tokyo, Japan

Schedule a meeting